Health
STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes – medwireNews
The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors…
medwireNews: The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.
Improvements in glycemic control were relatively small, with glycated hemoglobin (HbA1c) levels falling by an average of 1.6% (17.5 mmol/mol) among people randomly assigned to receive weekly semaglutide 2.4 mg for 68 weeks and 1.5% (15.9 mmol/mol) among those given…
-
Noosa News24 hours agoThis 42-Kilometre Walking Trail on the NSW North Coast Weaves Through Ancient Rainforest, Volcanic Mountains and Spectacular Waterfalls
-
Noosa News22 hours agoEaster weather forecast: What to expect in Sydney, Perth, Melbourne, Brisbane, Adelaide and Canberra
-
Noosa News22 hours agoQueensland cop cleared by court of stealing watches during anti-gang raid
-
Noosa News23 hours agoAnother power station confirmed offline as political fallout continues amid cultural issues